You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
醫藥板塊表現亮麗 藥明系、信達生物、金斯瑞、泰格及聯邦製藥漲逾5%-8%
市場憂慮華府停擺及美國經濟前景,美股三大指數昨晚齊挫1.1%-1.6%。亞太股市今早普遍受壓。然而,滬深股市反彈。恆指及國指也扭兩連挫,今早由年內低位反彈曾分別高見17,655及6,110,現報17,590及6,080,回升0.7%及0.8%,總成交額284億元。 醫藥板塊今天表現亮麗兼跑贏大市,尤其是藥明康德(02359.HK)繼昨天稍作整固後,今早再探頂,最高見92.6元(接近4月中旬所造高位92.8元),現報92.25元,升6.3%,該公司公佈,子公司合全藥業在常州和泰興兩個生產基地進行多(月太)生產車間產能擴建項目。藍籌藥明生物(02269.HK)重越10天及20天線,最高見45.8元,現報45.5元,回升5.9%。 聯邦製藥(03933.HK)四連升,最高見7.98元(暫受制上週一所創約三年高位8.48元),現報7.96元,續升8.3%。 信達生物(01801.HK)重越10天線(38.74元),最高見40.25元,現報40.1元,回升5.6%。金斯瑞生物(01548.HK)突破250天線(20.3元),最高見20.95元,現報20.5元,回升5.3%。泰格醫藥(03347.HK)一舉升破20天、10天及50天線(44.3元),最高見45.3元,現報44.65元,回升6%。 藍籌翰森製藥(03692.HK)四連彈兼挑戰50天線(10.74元),最高見10.82元,現報10.72元,續升3.7%。 君實(01877.HK)、諾誠健華-B(09969.HK)、科濟藥業-B(02171.HK)、和鉑醫藥-B(2142.HK)、微泰醫療-B(02235.HK)、開拓藥業(09939.HK)、百濟神州(06160.HK)、康希諾(06185.HK)及康方生物-B(09926.HK)漲約2%-3.5%,後者跑贏,股價升破250天線(37.65元),最高見38.7元,現報38.1元,回升3.5%。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account